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Introduction 
“Good evidence comes from good systematic reviews of good clinical trials”1 
 
The number of scientific publications concerning pain treatment is steadily accumulating. At 
the same time, it is becoming increasingly difficult for both researchers and clinicians to 
cover the wide spectre of literature, and to understand the implication of the findings of 
individual trials. Systematic reviews are designed to find the best possible evidence for a 
specific treatment. A systematic review is however reliant on the quality and validity of the 
individual trials it includes and on the methods it uses. In order to get good evidence we 
need good quality randomised, controlled trials. Investigating the complex, subjective 
phenomenon of pain in the context of a controlled clinical trial is potentially difficult and 
good trial methodology a challenge. 
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Abstract 
Aims 
To establish the evidence base for the use of the NMDA receptor antagonist ketamine in the 
treatment of acute postoperative pain and cancer pain, and in doing so, to assess the 
methodology used in acute pain and cancer pain trials. 
 
Methods 
In paper I a clinical model was developed and tested. Paper II is a quantitative and 
qualitative Cochrane systematic review on perioperative ketamine for acute postoperative 
pain. Paper III is a qualitative Cochrane systematic review on ketamine as adjuvant to opioid 
for cancer pain. Paper IV is a qualitative systematic review of the methodology used in 
clinical trials of oral opioids for cancer pain. 
 
Results 
The model developed in Paper I was tested and found to be sensitive. Thirty-seven 
randomised, controlled trials (RCTs) were included in paper II. The meta-analysis found that 
perioperative ketamine reduced 24 hr PCA morphine consumption and reduced PONV. In 
paper III, four RCT’s concerning ketamine as adjuvant to opioid for cancer pain were 
identified. Two were excluded due to flawed methodology. Both trials found that ketamine 
improved morphine analgesia. Meta-analysis was not appropriate. Thirty- four RCT’s were 
included in paper IV. Significant limitations in the trial methodology were identified. 
 
Conclusions 
There is level 1 (strong) evidence that perioperative ketamine reduces 24 hr PCA morphine 
consumption, and post-operative nausea and vomiting. Adverse effects were mild or absent. 
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There is currently insufficient evidence to permit conclusions regarding the benefits and 
harms of ketamine as adjuvant to opioid for cancer pain. Randomised, controlled trials are 
needed.  Clinical pain trials require rigorous methodology if they are to produce reliable 
results. Recommendations for future analgesic trials in acute and cancer pain are made. 
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CNS                                              Central nervous system 
CONSORT                                    Consolidation of Standards for Reporting Trials 
DRG                                              Dorsal root ganglion 
EBM                                             Evidence based medicine 
GABA                                             -aminobutyric acid
Hip                                                Hippocampus
IASP                                              International Association for the Study of Pain 
 10 
Ic                                                   Internal capsule
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1. Background 
1.1 Pain 
The International Association for the Study of Pain (IASP) defines pain as: 
”An unpleasant sensory and emotional experience associated with actual or potential tissue 
damage, or described in terms of such damage.” 
Much thought has gone into this definition, which attempts to capture the many different 
aspects of pain. Pain may be present with, or without tissue damage. The ability to feel pain 
is critical, in order to protect the body from injury. However, pain may change character and 
become persistent and refractory to treatment. Pain is subjective, and the perception of pain 
is influenced by the context in which the pain arises 2-4 5. This makes pain difficult to 
measure and may also make it difficult to treat. 
1.1.1 Anatomy and neurophysiology 
”Pain is not a passive consequence of the transfer of a defined peripheral input to a pain 
center in the cortex, but an active process generated partly in the periphery and partly 
within the CNS by multiple plastic changes that together determine the gain of the system.” 6 
 
Between the delivery of a painful stimulus and the subjective experience of pain is a series 
of complex events involving four distinct processes: Transduction, transmission, modulation 
and finally perception, when the pain signal is relayed to the brain resulting in the 
multidimensional experience of pain which involves sensory-discriminative, affective-
motivational and cognitive components7. 
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Figure 1. Pain pathways (adapted from ANZCA8) 
PAG: periaqueductal grey 
cc: corpus callosum 
Ce: central nucleus of the amygdala 
Hip: hippocampus 
ic: internal capsule 
LC: locus coeruleus 
DRG: dorsal root ganglion 
RVM: rostroventromedial medulla 
Pb: parabrachial area 
Po: posterior group of thalamic nuclei 
Py: pyramidal tract 
V: ventricle 
VMH: ventral medial nucleus of the hypothalamus 
VPL: ventral posterolateral nucleus of the thalamus 
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VPM: ventral posteromedial nucleus of the thalamus 
Bc: brachium conjunctivum 
 
Activation of the pain system: transduction and transmission 
Transduction  
Painful stimuli are registered by specific pain receptors (nociceptors), which are the free 
nerve endings of peripheral sensory neurons (A and C fibres). The nociceptors transform 
pain information into electrophysiological activity, depolarising currents. The central 
termination of these fibres is in the dorsal horn of the spinal cord where they synapse with 
central nervous system (CNS) neurones. 
 
Transmission  
If sufficient depolarising current, transduction is followed by initiation of action potentials 
and relay of coded information to the CNS. Initially impulses are conducted in primary 
afferent neurons to the dorsal horn of the spinal cord, from where secondary sensory afferent 
neurones ascend to the brainstem and thalamus. Thereafter, reciprocal connections are made 
between the thalamus and higher areas of the brain concerned with the perception of, and 
affective response to pain. Acute noxious inputs are mediated by glutamate acting on the 
AMPA (-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor. At the same 
time, inhibitory neurones releasing mainly glycine and -aminobutyric acid (GABA) are 
activated. 
 
Activation-dependent plasticity 
The nervous system changes its structure and function in response to the input it receives. In 
the case of activation of nociceptive pathways, there is a progressive increase in the response 
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to stimulation. Persistent neuronal activity leads to changes in neural function and results in 
the amplification of pain. This ”plasticity” is evident at all levels, from the periphery to the 
cortex.  
 
Activation –dependent plasticity in dorsal horn neurones 
Electrophysiological experiments have demonstrated a phenomenon entitled ”wind-up”, 
which is an example of activation-dependent plasticity in dorsal horn neurones. Intense or 
sustained nociceptive input results in the co-release of neuromodulators, as well as glutamate 
6
, the process being augmented by activation of the N-methyl-D-aspartate (NMDA) receptor. 
The net effect is that repeated C fibre stimulation results in a wind-up of action potential 
discharge and postsynaptic hyperactivity of dorsal horn nociceptive neurones. Wind-up may 
be inhibited by NMDA receptor antagonists such as ketamine 9. Long term potentiation 
(LTP) is a similar, but more persistent effect than wind-up, which can be evoked in a 
subpopulation of dorsal horn neurones by specific short- duration, high-frequency 
stimulation. 
 
Modulation: peripheral and central sensitisation 
The pain signal is potentially subject to modulation at a number of sites, both in the dorsal 
horn, and through supraspinal or descending control. Nociception does not always result in 
pain perception, and equally, pain may be perceived in the absence of nociception. 
Modulation of nociception occurs at all levels of the neuraxis.  
 
Peripheral sensitisation 
Peripheral nociceptors can be sensitised by injury, decreasing threshold and increasing 
response to noxious stimuli. The sensitising agents include inflammatory mediators such as 
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prostaglandins, bradykinin, serotonin, leucotrienes and Substance P, and neurotrophic 
factors released during tissue damage or by inflammatory cells. Primary afferents which are 
not usually stimulated by noxious and non-noxious stimuli may become activated. This 
process of sensitisation results in hyperalgesia (an increased response to a stimulus which is 
normally painful).  
 
Central sensitisation 
Activity-dependent enhancement of nociceptive transmission is common at excitatory 
synapses throughout the CNS, and increased activity of sensitised nociceptive primary 
afferent neurones results in increased excitability of spinal cord neurones. This modulation 
includes reduction in activation threshold, increased responsiveness, and expansion of the 
receptive field, resulting in enhancement of nociceptive input to higher centres. The 
increased excitability either outlasts the initiating input or requires low-level peripheral drive 
to maintain it 6. This process is termed central sensitisation and is responsible for allodynia 
(pain due to a stimulus which does not normally provoke pain) in the injured area.and the 
spread of hypersensitivity to areas beyond the site of injury. Central sensitisation is a major 
component of inflammatory and neuropathic pain. 
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Table 1.  Some of the important neurotransmitters in the dorsal horn mediating/ modulating 
pain (modified from Beaulieu and Rice 7) 
 
 
Neurotransmitter Receptor Effect on nociception 
Nonpeptides 
Monoamines: 
Noradrenaline 
Serotonin (5-HT) 
 
 
 
2-adrenergic 
5-HT1, (5-HT2), (5-HT3) 
 
 
Inhibitory 
Inhibitory 
 
Amino acids: 
GABA 
Glycine 
Glutamate 
Aspartate 
 
GABAA, GABAB 
 
NMDA, AMPA, kainate, mGluR 
NMDA, AMPA, kainate, mGluR 
 
Inhibitory 
Inhibitory 
Excitatory 
Excitatory 
 
Acetylcholine Muscarinic Inhibitory 
Peptides: 
Opioids: 
Enkephalins 
-Endorphins 
Dynorphin 
Non-opioids: 
Substance P 
CGRP 
CCK 
 
Galanin 
Somatostatin 
Neuropeptide Y 
Neurotensin 
Bradykinin 
 
 
(DOP) 
 (DOP),  (MOP) 
 (KOP) 
 
NK1 
CGRP 
CCKB 
 
GAL 
Sst 
Y1, (Y2) 
NTS1 
B2, (B1) 
 
 
 
Inhibitory 
Inhibitory 
Excitatory 
 
Excitatory 
Excitatory 
Excitatory or inhibitory dependent on 
site 
Excitatory or inhibitory dependent on 
site 
Inhibitory 
Inhibitory 
Inhibitory 
Excitatory 
Other: 
Adenosine 
Purines 
Cytokines 
Capsaicin 
Cannabinoids 
 
A1 
P2X3 
Interleukins, TNF 
VR1 
CB1 
 
Inhibitory 
Excitatory 
Excitatory and inhibitory 
Excitatory 
Inhibitory 
GABA: -aminobutyric acid 
CGRP: Calcitonin gene related peptide 
NMDA: N-methyl-D-aspartate 
AMPA: -amino-3-hydroxy-5-methyl-4-isaxazole propionic acid 
MGluR: metabotropic glutamate receptor 
CGMP: cyclic guanosine monophosphate 
NK: neurokinin 
CCK: cholecystokinin 
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The opioid and NMDA receptor systems, which show a close distribution pattern in the 
CNS, appear to be the two most important systems in modulating nociception, having 
respectively antinociceptive and pronociceptive actions.  
 
Excitatory systems: the role of the NMDA receptor 
Activity- dependent augmentation of nociceptive transmission may be divided into N-
methyl-D-aspartate (NMDA) receptor-dependent and NMDA receptor- independent types. 
NMDA is not an endogenous substance, but a research tool which has been used to identify 
a receptor active in glutaminergic transmission. The amino acids glutamate and aspartate 
are the major neurotransmitters in excitatory transmission at the spinal level. They are stored 
in the terminals of primary afferent nociceptors and are released in response to nociceptive 
activity. Glutamate is the major excitatory neurotransmitter and is utilized by 40% of all 
synapses10. There are three main receptors for glutamate on nociceptive C fibre afferents: the 
-amino-3-hydroxy-5-methyl-4-isaxazole propionic acid (AMPA), the metabotropic and the 
NMDA receptors.  
 
The NMDA receptor  
 NMDA receptors are located in the brain, spinal cord and on peripheral nociceptors and are 
concentrated at postsynaptic sites, although some appear to be pre-synaptic11. The receptor is 
an ionotropic (ligand gated ion channel) receptor composed of at least two families of 
subunits, the NR1 and NR2 subfamilies. The channel is permeable to Ca++ and to a lesser 
degree, to Na+ and K+. Glutamate binds to the NR2 subunit, while the NR1 subunit binds 
glycine, which is required as a co-agonist for receptor activation 12 (figure 2).The receptor is 
inhibited by Mg+ in a voltage-dependent manner. The NR1 and NR2 subunits occur in 
heterogenous forms, the NR2B subunit being implicated in pain perception and currently 
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being targeted for the development of new analgesics13. Excessive release of glutamate, or 
excessive stimulation of NMDA receptors within the nervous system, can lead to excitotoxic 
injury or cell death 12. NMDA receptor antagonists, including ketamine, have been shown in 
animal models of ischemic neuronal injury to have a neuroprotective effect14 15 16.  However, 
the clinical benefits of this have not been demonstrated.  
 
 
Figure 2: Schematic representation of the NMDA receptor showing NR1 and NR2B 
subunits. Closed ion channel on the left, and open on the right:  (modified from Loftis et 
al.13) 
Gly: glycine 
Glu: glutamate 
 
 
The NMDA receptor and hyperalgesic pain 
Acute noxious inputs are transmitted by the AMPA receptor. In contrast, the NMDA 
receptor does not appear to be involved in baseline transmission of pain signals, but in the 
modulation (amplification) of pain, being implicated both in central and peripheral 
sensitisation 17. The channel of the NMDA receptor is usually blocked by magnesium and it 
is thought that in response to a continuing painful stimulus, the magnesium block of NMDA 
channels is removed and the NMDA receptor activated (fig.2). 
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Both inflammatory pain and pain due to nervous tissue lesion are characterised by 
hypersensitivity at the site of injury and in the adjacent tissue. Inflammatory pain 
hypersensitivity usually returns to normal in conjunction with healing, while neuropathic 
pain persists long after healing, and is an expression of pathological enhanced activity in the 
nervous system. NMDA receptor antagonists such as ketamine and dextromethorphan have 
been shown to prevent or block enhanced, or hyperalgesic, pain states induced by tissue 
damage, inflammation, nerve damage and ischaemia9. The upregulation and activation of 
peripheral NMDA receptors contributes to the sensory changes (mechanical hyperalgesia 
and heat sensitisation) which usually accompany chronic inflammation17. Animal studies 
have demonstrated that the expression of peripheral NMDA receptors increases under 
conditions of inflammation18 17, and that peripheral NMDA receptors contribute to 
nociception in normal skin and maintain peripheral sensitisation in chronically inflamed 
skin17.  
 
The NMDA receptor and other modulatory functions 
The NMDA receptor is also implicated in other modulating functions such as learning and 
memory processing13. Excitatory glutamatergic neurotransmission is believed to be involved 
in the pathophysiology of depression: antidepressant treatments, including tricyclic 
antidepressants induce changes in NMDA receptor-binding characteristics, and modulate 
long term potentiation (LTP)19. Selective NMDA receptor antagonists have been shown to 
have antidepressant- like effects in animal behavioural models20 and case studies reporting 
improvement of major depression with ketamine infusions have recently been reported21. A 
deficit in NMDA transmission has been implicated in the pathophysiology of 
schizophrenia10.  
NMDA receptor- independent mechanisms of pain facilitation 
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NMDA receptor-independent mechanisms for facilitating pain transmission include certain 
dorsal horn AMPA receptors which allow calcium influx producing lasting facilitation of 
synaptic transmission in dorsal horn neurons. In addition, activation of A afferents may 
result in long-term depression of spinal inhibitory mechanisms, a process involving GABA/ 
glycinergic neurons in the substantia gelatinosa6. 
 
Inhibitory systems 
Opioids are the major inhibitory neurotransmitters. There are four major classes of opioid  
receptor: , 	,  and opioid-receptor-like (ORL1) receptors. Opioid receptors are widely 
distributed throughout the central nervous system, in somatic and visceral sensory neurones, 
spinal cord projection and interneurons, midbrain and cortex. Opioid receptors have also 
been identified on the peripheral endings of sensory neurones, the number of receptors 
increasing under conditions of inflammation or neuropathy22. Sympathetic neurones and 
immune cells can also express opioid receptors. 
u-opioid receptors dominate in the spinal 
cord, where they are found at the terminal zones of C-fibres, mainly in Lamina 1, and in the 
substantia gelatinosa. Opioid receptor agonist action inhibits the conduction of signals in 
nociceptive pathways in several ways, including the prevention of calcium influx at 
presynaptic calcium channels, which in turn inhibits the release of neurotransmitters23.  
 
Opioid receptors are believed to be reciprocally modulated by the NMDA receptor12. The 
NMDA receptor appears to be involved in the mechanism of opioid tolerance, and the 
blockade and reversal of opioid tolerance by NMDA receptor antagonists has repeatedly 
been demonstrated in animal models24 25 26. One hypothesis of opioid tolerance is that 
stimulation of opioid receptors triggers activation of antiopioid systems, that in turn produce 
hyperalgesia, thus reducing the net effect of the opioid27. Opioids have been shown to have 
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excitatory (pronociceptive) activity in animal models28 29, and numerous clinical reports 
confirm that chronic opioid administration may result in hyperalgesia.  
 
In addition, descending axons of serotonergic and noradrenergic neurones interact with 
primary afferent neurones in the dorsal horn to modulate the transmission of nociceptive 
information. This descending control of pain occurs primarily through two pathways 
originating in the midbrain (periaqueductal grey (PAG), and locus coeruleus (LC)), and the 
medulla (nucleus raphe magnus (NRM)) (fig.1). The main neurotransmitters involved in 
descending pain control are serotonin (5-HT), noradrenaline, dopamine and opioid peptides. 
 
Excitatory and inhibitory system interaction 
It has long been known that supraspinal centres modulate spinal nociceptive transmission via 
an endogenous opioid descending inhibitory system. More recently, it has been shown in 
animal studies that descending control is bi-directional via inhibitory and facilitatory 
systems, and that it is likely that these opposing systems are activated simultaneously by 
peripheral nociceptive afferent activity in conditions of acute nociception. In the case of 
persistent noxious input, it has been suggested that NMDA-receptor dependent neuroplastic 
changes could occur in the rostroventromedial medulla (RVM), which is an important 
midbrain relay station for descending modulation30. Such changes could lead to sustained 
facilitation of descending facilitatory pathways, a possible mechanism underlying some 
states of inflammatory and neuropathic pain30. In addition, the anterior cingulate cortex 
(ACC) which is involved in the processing of sensory and emotional components of pain, is 
widely connected to regions of the descending modulatory system. Recent animal studies 
indicate that activation of the ACC may also facilitate spinal nociception, and that NMDA 
receptors in the ACC may be involved in descending facilitation31. 
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Figure 3. A schematic diagram of the synapse between C fibre and dorsal horn neurone 
illustrating release of neurotransmitters and neuropeptides and interactions between 
excitatory and inhibitory systems (modified from Beaulieu and Rice7) 
 
MgluR: metabotropic glutamate receptor 
AMPA: -amino-3-hydroxy-5-methyl-4-isaxazole propionic acid receptor 
NMDA: N-Methyl-D-aspartate receptor 
NKA: Neurokinin A 
CGRP: Calcitonin gene-related peptide 
NK1: Neurokinin 1 receptor 
NK2: Neurokinin 2 receptor 
GABA: -aminobutyric acid 
 
1.1.2 Clinical pain 
In clinical practice, it is usual to distinguish between acute pain, chronic non-cancer pain and 
pain due to cancer. These types of pain respond differently to treatment and are handled 
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differently. Nociceptive pain arises in conjunction with stimulation of specific pain receptors 
(nociceptors). Neuropathic pain is initiated or caused by a primary lesion or dysfunction in 
the nervous system32. Neuropathic pain may be characterised by hyperalgesia, and/ or other 
signs of pathology such as allodynia. 
 
Acute pain 
Acute pain is defined as pain of recent onset and probable limited duration33 and arises in 
connection with tissue injury, involving the stimulation of nociceptors. Acute pain involves 
an inflammatory response and may also have a neuropathic pain component. Acute pain may 
progress to chronic pain, and there is a wealth of literature documenting chronic pain after 
surgery. For example, Tasmuth et al34 found that one third to half of  patients suffered from 
pain or paresthesia after modified radical mastectomy with axillary dissection or breast 
resection with axillary dissection. Kalso et al35 found that 28% of patients reported persistent 
post-sternotomy pain after coronary bypass surgery. Cunningham et al36 found that at 2 
years, 54% of patients had pain after hernia repair. In addition, a number of studies have 
identified pre-or postoperative pain intensity as a risk factor for chronic pain after surgery37. 
There is some evidence that specific early analgesic interventions may reduce the incidence 
of chronic pain after surgery8 38. Other factors such as genetic differences 39 and sex and 
gender40 may influence pain and the efficacy of pain treatment. 
 
Acute pain generally responds well to medical interventions, such as drugs (opioids, 
NSAIDs) and anaesthesiological techniques such as spinal, epidural and regional nerve 
blocks. In cases of refractory acute pain, it is important to consider the patient’s history, 
psychosocial situation and the acute pain setting, in order to identify factors which may be 
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exacerbating the pain. Opioid- dependent patients may for example experience severe pain 
after surgery because the post-operative opioid dose is too low compared to the baseline 
opioid requirement41. Psychological factors such as anxiety and catastrophising can 
contribute to the intensity of pain42. 
Cancer pain 
Pain due to malignancy may be both acute and chronic. Cancer patients commonly 
experience several types of pain concurrently. Tumour expansion can cause pressure on 
surrounding organs, while tumour infiltration in nerve plexi and bone, and damage of nerve 
tissue can cause neuropathic pain. Metastatic spread of cancer to bone is reported to be one 
of the most common causes of cancer pain43, and may cause pain both at rest and on 
movement. Cancer patients may experience muscular pain due to rapid weight loss. They are 
potentially subject to painful adverse effects of treatment, such as joint pain following 
chemotherapy, painful mucositis, and acute and/ or persistent neuropathic pain following 
radio- or chemotherapy. Cancer patients are often exposed to surgical interventions and 
experience acute, and in some cases chronic post-operative pain.  
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Table 2. Cancer pain  
  Examples of cancer pain subtypes                Possible pain mechanisms 
Tumour related Sensitisation of peripheral nociceptive 
primary afferents (inflammation associated 
factors, tumour factors,eg.endothelin and 
prostaglandins, tumour- induced acidosis ); 
invasion of mechanically sensitive tissues (e.g 
visceral pain); entrapment and nerve injury; 
central sensitisation. 
Metastatic bone pain Tumour-induced release of protons and 
acidosis; injury or infiltration of sensory 
neurones that innervate the bone marrow; 
peripheral sensitisation of nociceptors44; 
osteolysis, pathological fracture, 
microfractures. 
Metastatic soft tissue pain Peripheral sensitisation due to inflammation. 
Hyperalgesia due to central sensitisation. 
Inflammatory (e.g. mucositis) Peripheral sensitisation due to inflammation. 
Hyperalgesia due to central sensitisation. 
Neuropathy Nervous tissue compression or 
lesioncentral sensitisation. Disruption of 
tubulin function by chemotherapeutic agents, 
with release of cytokines, resulting in 
degeneration of sensory neurones and 
sensitisation of primary nociceptive 
afferents44. 
Muscle pain Tumour factors; central sensitisation; bone 
metastases causing muscle spasm; muscle 
hypercatabolism; immobilisation; increased 
muscular tension. 
Acute postoperative pain Acute nociception; peripheral sensitisation; 
nerve damage; (central sensitisation) 
Chronic postoperative pain Central sensitisation; nerve damage; 
(peripheral sensitisation) 
 
 
The World Health Organisation (WHO) three-step ladder for cancer pain relief 45 advises 
that mild cancer pain should be treated with non-opioid analgesics (paracetamol and/ or 
NSAIDs), moderate pain with the addition of weaker opioids, and strong pain with the 
substitution of stronger for weaker opioid. The utility of the second step on the ladder has 
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been challenged, with suggestions to replace step-two opioids with stronger opioid. 
Morphine is the”gold standard” opioid for cancer pain.  
 
Neuropathic pain  
Neuropathic pain is difficult to treat with opioids alone and usually requires adjuvant drugs 
such as tricyclic antidepressants (eg. amitriptyline), or anticonvulsants (eg.gabapentin or 
pregabalin). Refractory neuropathic pain requires other measures, such as adjuvant treatment 
with an NMDA receptor-antagonist, or anaesthesiological techniques such as spinally 
administered local anaesthetic as an adjuvant to opioid. 
  
Intermittent or breakthrough pain  
Breakthrough, or incident pain is common in cancer patients, with bone pain, local tumour 
invasion in soft tissue, and brachial plexopathy most frequently reported46. Breakthrough 
pain usually occurs at the site of the background pain and the duration may vary from 
minutes to hours47. Intense, short-lasting pain episodes and movement- related pain are 
particularly difficult to treat effectively with analgesics. Normal-release oral opioid or oral 
transmucosal fentanyl citrate are at present the most common pharmacological treatment 
options for breakthrough pain. 
The potential complexity of the cancer patient’s pain syndrome (table 2) underscores the 
importance of repeated clinical assessment and pain diagnosis, together with an individual 
treatment plan. 
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Chronic non-cancer pain 
The IASP defines chronic pain as pain without apparent biological value that has persisted 
beyond the normal tissue healing time (usually considered to be 3 months). Chronic pain is a 
complex condition which may be related to tissue damage, injury to the nervous system, 
affective state and interactions of the individual with the environment. Chronic pain often 
requires a multidisciplinary approach including a comprehensive and individually tailored 
treatment programme which may involve pharmacological, psychological and physical 
interventions. 
 
1.2 Ketamine 
1.2.1 General 
Ketamine is a phencyclidine (PCP) derivate, developed in the 1960’s as an anaesthetic agent. 
Ketamine has multiple pharmacological effects and interacts with a large number of 
receptors and channels, including nicotinic and muscarinic acetylcholine receptors, opioid 
receptors, monoaminergic and voltage-sensitive calcium channels, and sodium channels. 
Ketamine has a direct action on the NMDA receptor, binding to the PCP binding site in the 
NMDA channel, thus inhibiting glutamate activation of the channel in a non-competitive 
manner. The analgesic effect of ketamine is thought to be due to this antagonistic effect on 
the NMDA receptor. This is due to the fact that both ketamine isomers have been found to 
have higher affinity for the NMDA receptor PCP binding site than for other sites and 
channels48 49, and that ketamine analgesia appears due to a non-opioid mechanism48 50 51.  
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NMDA receptor activation is believed to be central to the generation and maintenance of 
hyperalgesic pain9, and NMDA receptor antagonists, such as ketamine, have been shown to 
inhibit hyperalgesia/ allodynia52. Non-competitive NMDA receptor antagonists, including 
ketamine, have also been shown in animal studies to attenuate the development of opioid 
tolerance 53. These factors make ketamine an interesting drug for the treatment of refractory 
pain. 
Ketamine was previously only available as a racemic mixture of the two stereoisomers, S(+) 
and R(-) ketamine. Both isomers and the metabolite, norketamine, have been shown in 
animal studies to be NMDA receptor antagonists 54. Most clinical studies on the analgesic 
effects of ketamine have used racemic ketamine. More recently, the S(+) ketamine isomer 
has been approved for clinical use. The S(+) isomer is approximately  twice as potent as the 
racemic mixture55. S(+) ketamine produces longer hypnosis than the R(-) isomer, and causes 
a greater rise in blood pressure and heart rate, less locomotor activity, and a shorter recovery 
time, but equipotent analgesia. An investigation using positron emission tomography in 
healthy volunteers, has shown that S(+) ketamine binds to specific areas in the brain 
corresponding to regions with a high density of NMDA receptors56. S(+) ketamine is 
generally thought to have a safer adverse effect profile than racemic ketamine57, although 
there seems to be little clinical trial data  to support this. A recent study by Lahtinen et al58 
found an eight percent incidence of psychotomimetic adverse effects in patients treated with 
S(+) ketamine after cardiac surgery. 
1.2.2 Pharmacokinetics  
Pharmacokinetically, ketamine has short distribution and elimination half-lives, the alpha-
elimination phase lasts only a few minutes and the beta-elimination half-life is 2-3 hours. 
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Ketamine undergoes extensive hepatic metabolism by the cytochrome p450 system, 
primarily via N-demethylation to norketamine, and has been shown to have stereoselective 
pharmacokinetics. Both ketamine and metabolites are renally excreted. 
 
Norketamine is also an NMDA receptor antagonist, having a 2-4 fold lesser affinity for the 
non-competitive site of the NMDA receptor than ketamine, and being only one third to one 
fifth as potent as ketamine. Norketamine has been shown to have dose-dependent 
antinociceptive effects59. Other metabolites of ketamine are mainly hydroxynorketamines 
which have poor lipid solubility and do not have CNS activity. Ketamine enantiomers differ 
in their hepatic clearance and duration of anaesthetic effect. S(+) ketamine exhibits a greater 
clearance and faster anaesthetic recovery compared to the racemate and a greater clearance 
compared to R(-) ketamine60. R(-)-ketamine inhibits the elimination of S(+)-ketamine61.  
 
The pharmacokinetics and analgesic effects of intramuscular and oral racemic ketamine in a 
dose of 0.5 mg kg-1 were examined in a group of six healthy volunteers62 in a randomised, 
single-blind, placebo-controlled crossover study. Pain thresholds measured by the tourniquet 
test were increased at 15 min and 30 min after i.m.injection and at 30 min after oral 
ketamine. The plasma ketamine concentration associated with analgesia was 150 ng ml-1 
following the i.m. dose, but only 40 ng ml-1 after the oral dose. Oral administration was 
associated with much greater concentrations of the metabolite norketamine which it was 
speculated may have contributed to the analgesia. This single-blind study has resulted in 
some confusion regarding the potency of oral ketamine and has been cited in support of a 
claim that oral ketamine is more potent than parenteral ketamine63.  
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The same research group the following year published a randomised, double-blinded placebo 
controlled crossover study in healthy volunteers, investigating the pharmacokinetics of 
intramuscular racemic ketamine (N=6) compared to intravenous (N=5) or oral racemic 
ketamine (N=6)64. Absorption after intramuscular injection was rapid and the bioavailability 
was 93%. However, only 17% of an oral dose was available due to extensive first-pass 
metabolism. In this study, pain thresholds measured in the same tourniquet test showed 
marked elevation for 15-60 min after intramuscular injection, but little or no effect after the 
oral solution. Pain threshold elevation occurred at plasma ketamine concentrations above 
160 ng/ml. In contrast to the previous study, the authors concluded that, in view of the 
extensive first-pass metabolism, oral administration of ketamine in a dose of 0.5 mg/kg is 
not satisfactory for producing analgesia. 
 
A randomised, controlled trial investigated intranasal ketamine for breakthrough pain65. 
Plasma concentrations of ketamine were measured at two, 30 and 60 minutes after intranasal 
spray administration. Plasma levels were detectable by 2 minutes after administration and 
the observed mean concentration of ketamine was greatest at 30 minutes after 
administration, corresponding to the interval of greatest decrease in pain intensity scores. At 
the last observed time (60 minutes), mean ketamine levels had declined by approximately 
20% from peak values.  
 
In a preclinical study 66, the pharmacokinetics of ketamine and alfentanil, alone and together, 
in three groups of adult male rats, were determined to assess any pharmacokinetic 
interaction. The distribution of ketamine into the brain was increased by low, constant 
plasma concentrations of alfentanil. To date there is no human data on the pharmacokinetics 
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of ketamine co-administered with morphine. Such a study would be interesting, and may 
further our understanding of the apparent synergism of these two drugs. 
 
The pharmacokinetic data on ketamine and isomers is limited. For example, a search of 
PubMed in April 2006 revealed no studies where intravenous S(+) ketamine was compared 
with oral S(+) ketamine. Since both racemic and S(+) ketamine are increasingly being used 
in the treatment of refractory pain, there is a need for more data. 
 
1.2.3 Toxicology and abuse 
The clinical use of ketamine is thought to be limited by psychotomimetic and other adverse 
effects which include hallucinations, agitation, nightmares, dizziness and nausea. At higher 
doses (>2 mg/kg, IV)67 ketamine can cause delirium, impaired motor function, amnesia, 
anxiety, panic attacks, mania, insomnia, and high blood pressure.  
 
NMDA receptor antagonists including ketamine, GABA receptor agonists and ethanol have 
all been demonstrated in studies in immature rodents to trigger widespread apoptotic 
neurodegeneration throughout the developing brain68 69.  In addition, there is controversy in 
the literature regarding the safety of epidural and spinal administration of ketamine70, some 
animal studies and isolated clinical reports having described toxic effects71 72 73 74.  
 
Ketamine is increasingly used as a drug of abuse in Western countries75 and was recently re-
classified as a controlled drug in the UK. Although the mortality rate is low, there are 
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concerns regarding the neurotoxic effects. Recreational users report flashbacks which can 
recur days or weeks after use76. Frequent abuse of ketamine has been shown to cause long-
lasting memory impairment77 and a recent PET study found altered prefrontal dopaminergic 
function in chronic recreational users of ketamine78.  
 
It was previously thought that tolerance does not develop to ketamine. However, animal 
studies indicate that ketamine can give rise to a dependence syndrome without physical 
withdrawal phenomena79. Reports from recreational users confirm that tolerance builds 
rapidly and can be very high, and that users can experience psychological dependence and 
craving, with little documented evidence of physiological withdrawal symptoms80. 
Recreational users usually administer ketamine intranasally, although it is also injected. A 
randomised controlled trial has been published investigating the use of intranasal ketamine 
for breakthrough pain65. Although intranasal ketamine may have potential for the relief of 
breakthrough pain in terminally ill cancer patients, it would seem prudent to exercise caution 
with regard to use of this rapid- acting route of administration in the treatment of chronic 
non-cancer pain81. 
 
1.2.4 The clinical use of NMDA receptor antagonists 
Given the role of the NMDA receptor in central sensitisation, in opioid tolerance, and 
possibly in the chronification of pain, NMDA receptor antagonists are potentially interesting 
drugs for the treatment of refractory pain. A number of NMDA receptor antagonists 
including dextromethorphan, ketamine and memantine are clinically available, although it is 
generally believed that psychotomimetic adverse effects limit their usefulness. Memantine 
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has recently been approved for the treatment of dementia12 and future possiblities for the 
treatment of neurological disorders such as multiple sclerosis, with NMDA receptor 
antagonists have been identified82.  
 
A recent qualitative systematic review on dextromethorphan83 concluded that it has the 
potential to be a safe adjunctive agent to opioid analgesia in postoperative pain management. 
Ketamine is the most studied NMDA receptor antagonist in clinical pain trials, and is 
commonly used for the treatment of refractory cancer pain, and as an opioid-sparing drug in 
the treatment of acute postoperative pain, although it is not licenced for these uses. Using 
drugs beyond licence in palliative care and in the management of refractory pain is both 
common and necessary84, however the aim should be to use techniques with documented 
efficacy. 
 
1.3 Evidence 
 
1.3.1 What is evidence-based medicine (EBM)? 
The British epidemiologist Archie Cochrane, and the Canadian epidemiologist David 
Sackett, are credited with establishing what is now known as evidence-based medicine 
(EBM). In 1972, Cochrane published a classic text where he suggested that, since resources 
are limited, they should be used to provide those forms of health care which have been 
shown in properly designed evaluations to be effective. In particular, he stressed the 
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importance of using evidence from randomised controlled trials, because these were much 
more likely to provide reliable information than other sources of evidence85.  
 
In 1979 Cochrane called on physicians to assemble ” a critical summary, adapted 
periodically, of all…relevant randomized controlled trials”86.  In the 1980’s, a body of 
systematic reviews in pregnancy and childbirth were produced at the National Perinatal 
Epidemiology Unit in Oxford87. The Cochrane Collaboration was later founded in 1993 and 
is an international, independent, non-profit organisation devoted to tracking down, 
evaluating and synthesising RCT’s in all areas of medicine. This process centres on the 
production and dissemination of systematic reviews of healthcare interventions.  
 
1.3.2 Systematic reviews 
A systematic review is a review of a particular subject performed in a thorough and 
systematic manner so that the risk of bias is reduced. Systematic reviews and large 
randomised trials constitute the most reliable sources of evidence for the benefits and harms 
of a specific treatment (table 3). 
Table 3. Type and strength of efficacy evidence  
(Adapted from Bandolier,accessed 3rd March 2006) 
I Strong evidence from at least one systematic review of multiple 
well-designed randomised controlled trials 
II Strong evidence obtained from at least one properly designed 
randomised controlled trial of appropriate size 
III Evidence obtained from well-designed trials without randomisation, 
single-group pre-post, cohort, time series, or matched case-
controlled studies 
IV Evidence from well-designed non-experimental studies from more 
than one centre or research group 
V Opinions of respected authorities, based on clinical evidence, 
descriptive studies, or reports of expert committees 
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A systematic review involves a comprehensive search and examination of all available 
published literature on a specific topic followed by extraction of RCT’s, and subsequently a 
critical evaluation of study quality and validity, with exclusion of trials not having high 
scientific quality. 
 
Quantitative and qualitative systematic reviews  
It is not always possible or advisable to pool data from different trials. For example, if the 
trials have used different outcomes, or have followed the patients for different lengths of 
time, then combining the results may lead to faulty conclusions. A systematic review where 
it was not possible to pool data from different trials is termed a qualitative review. The result 
of this type of review then depends upon ”vote- counting”, assessing whether the result of a 
trial comparing treatment A to treatment B was ”positive” ( showing that A is better than B), 
or ”negative”(showing no difference between treatments).  
 
Where possible, information from many trials is statistically combined (meta-analysis). A 
systematic review which includes meta-analysis is termed a quantitative systematic review. 
Quantitative systematic reviews often present the result of meta-analyses in statistical terms 
such as odds ratio (OR) or weighted mean difference (WMD), which are difficult concepts to 
relate to clinical practice. In Cochrane reviews it is usual to present the results of meta-
analysis in the form of a Forest plot which graphs odds ratios (with 95% confidence 
intervals) from several studies. Two tools, L’Abbe plot 88 and the number needed to treat 
(NNT) / number needed to harm (NNH)89 90, make the results of meta-analyses more 
accessible.  
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Systematic reviews: sources of bias and limitations 
Interpreting a systematic review has its own pitfalls. Two systematic reviews on the same 
topic can come to different conclusions. This is usually related to the methods of the review, 
which may differ, and this may be very confusing for the clinician. In 1996 a systematic 
review of the methodology used in systematic reviews of analgesic interventions found that 
most had methodological flaws, and that poor quality systematic reviews reached 
significantly more positive conclusions91.  
 
Systematic reviews are themselves subject to bias, and a review is only as good as the data 
upon which it is based and the methods it uses. The reviewer may be biased, therefore a 
systematic review should have more than one author, and the authors should be equally 
involved in the assessment of trials, and in choosing which trials should be included in the 
review. The selective publication of studies with positive outcome, is another potential 
source of bias (publication bias) which can lead to overestimation of treatment effect in 
meta-analyses92. Expert opinion has previously advised that funnel plots should be used to 
check for publication bias, with absence of publication bias providing symmetry and the 
presence of publication bias asymmetry. An empirical evaluation has now demonstrated that 
asymmetry exists in funnel plots with or without publication bias93. 
 
Including trials of low quality /validity and excluding trials which are published in other 
languages than English, are other potential sources of bias. Furthermore, systematic reviews 
need to be regularly updated, as the trial literature accumulates. Moher et al have recently 
proposed a definition of what should constitute an appropriate update94. 
 
 41 
The methods of the review determine the reliability, and these should be transparent. Oxman 
and Guyatt95 have suggested a quality index by which to assess scientific reviews. More 
recently, the Quality of Reporting of Meta-analyses (QUOROM)92 statement was published,  
providing guidelines for the reporting of meta-analyses of clinical randomised controlled 
trials.  
 
1.3.3 Trial assessment for inclusion in systematic reviews: quality 
and validity    
Methodological rigour is an essential element of the evidence-based medicine approach, an 
important objective being to as far as possible eliminate sources of bias. Bias may be defined 
as  ”a one-sided inclination of thought, a prejudice, or any special influence that sways a 
decision” 96. Randomised, double-blinded, controlled trials (RCT’s) are designed to 
eliminate or minimise selection and observer bias.  
In designing or assessing a clinical trial the following factors are important:  
 
a. randomisation and allocation concealment  
To avoid selection bias, patients in clinical trials should be allocated at random to the 
different study groups. The process of randomisation should be appropriate, and described in 
the trial report and the details of allocation assignment should be concealed until the time of 
allocation 1  97. Non-randomised studies overestimate treatment effect by 41% 97. 
 
b. blinding 
Blinding is necessary to avoid observer bias. Trials that are not double-blind overestimate 
treatment effect by 17%97. 
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c. control  
The control group reflects what happens without treatment and /or how a new treatment 
compares with an established treatment. Several factors can contribute to what happens in 
the control group (table 4). 
  
Table 4: Sum of effects in the control group (adapted from Kalso et al 98) 
Control Effects  
Waiting list Natural course of disease minus the effect of 
nothing being done (potentially negative 
effect) 
Visits without treatment Natural course +  patient interaction with 
doctor/ nurse 
Placebo treatment Natural course + interaction + expectation of 
effect 
Active control Natural course + interaction + expectation + 
actual effect 
 
Table 4 illustrates the importance of an appropriate control group if we are to find out about 
the actual effect of a treatment.  
 
The placebo 
 Ideally, clinical studies of pain treatment should include a placebo and an active control 
group. The placebo effect is particularly important in studies of pain, since people in pain 
respond to placebo99. The placebo analgesic response is highly variable and cannot be 
predicted, therefore a placebo group is usually needed in order to show the effect of an 
analgesic treatment. 
Beecher described the placebo as a ”tool to get to certain fundamental mechanisms of the 
actions of drugs, especially those designed to modify subjective responses”99. He recorded 
the effects reported by postoperative patients receiving placebo treatment, including both 
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pain relief and adverse effects and concluded that ”the placebo effect of active drugs is 
masked by their active effects ” and that ”the power attributed to morphine is presumably a 
placebo effect plus a drug effect”99. 
 
As shown in Table 4, the placebo effect may be considered the sum of patient expectations 
and patient/ health care worker interaction. A large number of studies have investigated the 
placebo effect which has proved to have a variable responder rate100 98. There has been much 
discussion regarding the use of placebo controls in medical trials. A placebo control can 
often provide the clearest insight into what a treatment can accomplish, especially in relation 
to a subjectively perceived condition such as pain. It is common to use placebo controls in 
acute pain and chronic non-cancer pain trials.  
e. group size 
The main cause of variability in response to pain treatment in clinical trials is most likely to 
be random chance 101. Small trials may overestimate treatment effect by about 30% 101 102. 
. 
Assessment of quality and validity in clinical pain trials 
In the case of assessment of clinical pain trials for inclusion in systematic reviews, specific 
tools such as the Oxford quality scoring system for controlled trials103 and the Oxford Pain 
Validity scale (OPVS)104 have been developed. The Oxford quality scoring system is a three-
item (1-5) scale which evaluates randomisation/allocation concealment; details of blinding 
measures, and withdrawals and dropouts, providing an overall quality score.  
 
A study may have high quality, but yet have poor validity, lacking adequate trial design to 
answer the research question. The OPVS is a 5 item (1-16) scale developed to measure 
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validity of findings from randomised controlled trials, and to enable ranking of trial findings 
according to validity within qualitative systematic reviews. The OPVS is designed to be used 
for randomised trials with at least 10 patients per group, and includes 5 items for assessment: 
blinding, size of trial groups, outcome measures, baseline pain and internal sensitivity, and 
data analysis. Internal trial sensitivity is important. There must be enough baseline pain in 
order to detect a difference between baseline and post-treatment pain, and the trial design 
should be able to detect a difference between groups, should there be one. One way of doing 
this is to have an additional active control group which shows a significant difference from 
placebo105.  
 
 
1.3.4 The application of EBM to healthcare   
Evidence-based medicine is intended applied in the context of clinical experience and 
critical judgement. The practical application of EBM requires a combination of scientific 
facts with value judgements and must take into consideration other important factors such as 
patient preferences and available resources105. 
 
”The practice of evidence-based medicine means integrating individual clinical expertise 
with the best available external clinical evidence…Good doctors use both individual clinical 
expertise and the best available external evidence, and neither alone is enough.”106  
Views on EBM are polarised, issues of contention including the limitations of efficacy data 
from randomised trials as evidence, and concerns regarding the use of the concept of clinical 
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evidence and guidelines to restrict physician autonomy. Some clinicians feel that EBM 
”casts a cold light ” over their clinical practice107, or that it is reductionistic and dogmatic.  
 
The number of systematic reviews in pain relief in the Cochrane database is steadily 
increasing. Another useful source of systematic reviews in pain relief is the Bandolier 
108/Oxford Pain Internet Site109. In some areas of medicine it is difficult or impossible to 
investigate specific treatments in the context of a randomised controlled trial. For example, 
in the field of interventional pain treatment, there are virtually no RCTs. This is due to 
methodological difficulties, or to other factors hindering research. When this is the case, 
treatment should at least occur in the context of clinical audits with uniform standards and 
assessments. Audits can provide data on safety issues, but not reliable efficacy data. The 
way data from audits are reported and presented is therefore important. Well conducted 
audits can lead to quality improvement of treatment1. 
 
In carrying out a systematic review, it soon becomes apparent how difficult it is to perform 
good clinical pain research and how vital it is to establish uniform standards of quality. 
Systematic reviews by necessity focus on the need for rigorous clinical trial methodology. It 
has even been suggested that the most important role of EBM is to sharpen and define the 
clinical research agenda. The CONSORT  (Consolidation of Standards for Reporting Trials) 
initiative has established standards for the reporting of clinical trials110. The Initiative on 
Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT), has developed 
recommendations for core outcome domains111 and measures112 in chronic pain trials in 
order to encourage more complete reporting and to facilitate comparison and pooling of data.  
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1.4 Methodology 
1.4.1 General 
Pain is an individual and subjective experience influenced by physiological, psychological 
and contextual factors. This makes pain difficult to investigate in the context of a controlled 
clinical trial. What should we be measuring in clinical pain trials, and which factors should 
be assessed or attempted controlled? 
 
Trials should be randomised to control for selection bias, and double-blinded to control for 
observer bias. If possible, there should be a placebo group to control for the factors 
summarised in table 4. The trial should have sufficient power to detect a difference between 
treatment groups. The required trial size depends on the size of the effect, and on how sure 
of the result we need to be. For a clinically relevant result, an estimate of the size of the 
difference between treatment and placebo is needed. If the treatment effect is weak, and/or 
there is considerable variability in the levels of pain, then larger numbers of patients will be 
required to demonstrate a clinically relevant treatment effect101. Acute pain trials 
traditionally use only about 40 patients per arm101, while in cancer pain groups are usually 
even smaller. One way around the problem of trial size is standardisation of trial design and 
pooling data from multiple trials of small size (meta-analysis). Alternative measures of 
analgesic efficacy suitable for large-scale trials (”mega-trials”) have also been suggested. 
For example a simple global subjective efficacy rating (”How effective do you think the 
treatment was?) has been shown to provide similar measures of analgesic efficacy as total 
pain relief (TOTPAR) derived from hourly measurements113. 
Trial sensitivity is an important issue. In order to show a difference between treatments 
reducing pain intensity, there should be sufficient baseline pain intensity 114. A systematic 
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review of  randomised trials investigating the effectiveness of intra-articular morphine in 
arthroscopic procedures of the knee joint found that only 15 of 25 trials were sensitive, and 
that a minimum of 30% of the maximum possible pain intensity is needed for an analgesic 
effect to be detected in a study115. The question of analgesic dose is also relevant- in the 
same systematic review it was found that most studies with positive outcome had used 
higher doses than the negative studies115.   
 
Common outcomes in pain trials include pain intensity assessed using subjective, validated 
measures of pain on movement and at rest e.g., visual analogue scale of pain intensity 
(VASpi) or other validated scales, and/ or pain relief. The commonest tools to measure pain 
intensity and pain relief are categorical and visual analogue scales. Categorical scales are 
quick and simple, however, the limited number of choices may make these less sensitive 
than VAS and numerical scales116. Pain relief scales have the same baseline relief value 
(zero) and are therefore easier to compare and possibly more sensitive than pain intensity 
scales 1. If rescue medication is given, then total consumption of rescue medication may be 
an appropriate outcome115. Another useful outcome is time to remedication which gives an 
estimation of analgesic duration. All pain treatment is a question of balancing effect and 
adverse effects. Major and minor adverse effects are therefore important outcome measures, 
and where possible should also be reported as dichotomous data, thus enabling meta-
analysis. Specific guidelines for reporting adverse effect information in clinical trials have 
been published117. 
 
Recommendations have been made for core outcomes and measures in trials of chronic 
pain111 112, while specific consensus recommendations for trials in acute and cancer pain are 
lacking. For chronic pain trials six core outcome domains are recommended: (1) pain, (2) 
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physical functioning, (3) emotional functioning, (4) participant ratings of improvement and 
satisfaction with treatment, (5) symptoms and adverse events, (6) participant disposition 
(adherence to the treatment regime, reasons for withdrawal from trial). The Beck Depression 
Inventory (BDI)118 and the Profile of Mood States (POMS)119 are recommended as core 
outcome measures of emotional functioning in chronic pain.  
 
 
1.4.2 Acute pain trials: special issues    
Nociceptive pain is most common in the acute setting, but neuropathic pain due to nerve 
injury may also be present. The usual model for acute pain is pain after surgery. Stubhaug 
and Breivik114  have described issues of importance for acute postoperative pain trials.  
Acute pain occurs within a defined time frame and acute pain trials are of short duration. 
Parallel group studies are the most common, while selected crossover studies may be 
performed in patients undergoing repetitive uniform surgical interventions such as wisdom 
tooth extraction. A crossover design has the advantage that the patient is his/her own control. 
Sufficient baseline pain (trial sensitivity) is important. If patients are given an analgesic 
treatment before an initial pain level can be established (for example in the case of 
preemptive analgesia), the results will be difficult to interpret. Not all patients require 
analgesia after surgery, and this type of design may lead to patients not needing analgesics 
being included in the trial.  
 
Polypharmacy is common in the perioperative period and it is therefore important to 
standardise the anaesthetic regime as much as is feasible. Single dose analgesic studies are 
easy to perform and often used in acute pain. However a single dose study does not closely 
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mimic the true clinical setting, and adverse effects may be missed114. Patient controlled 
analgesia (PCA) studies are useful, allowing observation over time and measures of 
analgesic consumption. The limitations of PCA trials include lack of sensitivity, and the 
number of factors which may influence analgesic consumption in this model, such as bolus 
size, lockout time, psychological factors and degree of sedation caused by the test drug, thus 
influencing the patient’s ability to administer the analgesic.  
 
Questions of which drug, timing of administration, and duration of follow-up are relevant.  
Stubhaug et al.114 described the phenomenon of chronic pain after surgery and the need for 
new methods to study this. Chronic pain after surgery is common 120. The concept of 
preemptive analgesia was described by Woolf et al in 1993 121. Preemptive analgesia is 
initiated before and during the surgical procedure with the aim of reducing nociceptive input 
and preventing or limiting central sensitisation. Studies on preemptive analgesia have 
however proved inconclusive, and it is now recommended that future studies should redirect 
their focus from the timing of perioperative analgesia to ”protective” analgesia122, using 
different types of drugs such as NMDA receptor antagonists or gabapentinoids, with the aim 
of preventing hypersensitivity to pain123. The following have been suggested as appropriate 
requirements for studies of chronic postoperative pain: preoperative data including 
assessment of pain and psychological risk factors for chronic pain; description of the 
operative process; assessment of acute postoperative pain and management and standardised 
follow-up at intervals to one year or more120 123.  
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1.4.3 Cancer pain trials: special issues    
In palliative care there are special methodological issues related to clinical pain research. For 
example, it may be difficult to recruit patients to trials due to inclusion criteria, and dropout 
rates are high. There may be high rates of anxiety and or depression in this patient 
population. 
 
Cancer patients require analgesic drug treatment over long periods of time. Trials are 
however usually of relatively short duration due to disease progression and high rates of 
withdrawal. Cancer patients often receive other types of treatment which may reduce, or 
increase pain during an analgesic trial. These potentially confounding factors must be 
considered when deciding inclusion and exclusion criteria for a trial. Cancer pain trials 
traditionally have small numbers of patients. 
 
Many analgesic trials in cancer pain are equivalence studies, comparing two formulas of the 
same drug. There are a number of methodological issues concerning equivalence trials124. 
The first issue concerns the use of an active comparator. The assumption when using an 
active comparator opioid in a cancer pain trial is that the comparator has previously been 
shown to be effective in the same context in a randomised double- blind placebo-controlled 
trial. The second issue concerns the design of equivalency trials using an active comparator. 
The design should as far as possible mirror that of earlier trials demonstrating the 
comparator’s efficacy against placebo124. The third methodological issue concerns trial size, 
since equivalency trials generally need to be larger than their placebo-controlled 
counterparts124. The latest revision of the CONSORT statement addresses the particular 
difficulties of equivalence trials and contains a checklist for reporting this type of trial125. 
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The pitfalls of performing equivalence trials in the palliative care patient population are 
obvious.  
 
The use or non-use of a placebo control in cancer pain trials is controversial. Researchers are 
generally reluctant to use placebo in opioid trials, preferring to use an active comparator. 
This decision is based upon the assumption that opioids are effective analgesics in cancer 
pain, and that it would be unethical to use a placebo control. While it is generally not ethical 
to use a placebo control in trials of oncological treatment because of the greater risk to the 
patient due to treatment delay, in trials of the pharmacological treatment of cancer pain a 
placebo control may be both feasible and useful.  
 
The Declaration of Helsinki126 amendment of 2000 originally stated that the placebo should 
be used prudently in research trials, and only in cases where there was no proven therapy for 
the condition under investigation. In a situation where there already exists an effective 
treatment (that is a drug shown to be effective when compared to placebo), it was 
recommended to use the active comparator as a control. Following considerable polemics, 
the World Medical Association (WMA) subsequently published a clarification of this 
statement, where it was agreed that there were circumstances where a placebo-controlled 
trial might be ethically acceptable, even if proven therapy was available. In the clarification 
statement of 2002, it is stated that the use of placebo control could be justified 
 ”  where for compelling and scientifically sound methodological reasons its use was 
necessary to determine the efficacy or safety of a prophylactic, diagnostic or therapeutic 
method; or where a prophylactic, diagnostic or therapeutic method was being investigated 
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for a minor condition and the patients who received placebo would not be subject to any 
additional risk of serious or irreversible harm.” 
  
”Scientifically sound methodological reasons” is a key phrase in this statement. Concurrent 
with the need for high ethical standards is an equally important need for scientific rigour. 
Exposing patients to large numbers of trials having considerable methodological limitations, 
and the potential for producing unreliable data, may also be considered unethical.  
 
In summary, despite the obvious difficulties associated with clinical pain research in the 
palliative care patient population it is important to maintain high scientific standards and to 
ensure that research questions relevant to clinical practice are asked. Researchers conducting 
efficacy trials of pharmacological pain treatment in cancer pain should always consider the 
feasibility of using a placebo control.  
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2. Aims of the present study  
1. To contribute to existing trial methodology by developing and testing a clinical model 
where the same patient could serve as her own control, for use in the study of acute and 
chronic postoperative pain. 
2.  To prepare a systematic review on postoperative pain with focus on use of the NMDA 
receptor antagonist ketamine, in order to establish the current evidence base for this 
practice and in doing so, to assess the methodology. 
3. To prepare a systematic review on cancer pain treatment with focus on the use of 
ketamine as adjuvant to opioid for refractory pain, to establish the evidence base for this 
practice and, in doing so, to assess the methodology 
4. To evaluate the quality and validity of trial methodology used in cancer pain analgesic 
trials, by performing a systematic review. 
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3. Methods   
Paper I : Eight female patients scheduled to undergo elective bilateral surgery participated. 
All patients received a standardised general anaesthesia. Breasts were randomised to 
preoperative infiltration with active treatment (lidocaine and adrenaline), or placebo (saline 
and adrenaline). Preoperative assessment included (baseline) quantitative sensory testing 
(QST) using a thermotester, which was repeated postoperatively and after six months, and 
pain intensity measurement at baseline, at several time points after surgery and at six 
months. At the same time points, additional sensory testing with brush and von Frey 
filaments was performed. Pain intensity measurements of breast pain were regularly 
performed at rest, on coughing and on elevation of the ipsilateral arm, using a visual 
analogue pain scale (VAS).  For the statistical analysis of measurements over time (VAS 
pain intensity scores), the area under the curve (AUC) was calculated. The difference 
between saline and lidocaine responses was evaluated using the Wilcoxon signed rank test. 
P<0.05 was considered to be significant. 
 
 
Papers II, III and IV: Systematic reviews: For papers II and III, comprehensive and 
systematic searches of the scientific literature were performed by one reviewer (RFB) with 
assistance from the Cochrane Pain Palliative and Supportive Care Collaborative Review 
Group, Oxford. For paper III the searches were performed by one reviewer (RFB) and by a 
researcher at the Pain Management Unit at the Royal National Hospital  for Rheumatic 
Diseases, Bath, UK. All titles were examined by two reviewers (RFB and EK) and potential 
trials retrieved. In addition, reference lists of relevant textbooks, reviews and trials were 
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handsearched for possible trials. For papers II and III, the manufacturer of ketamine was 
contacted for access to published and unpublished data in the PARDLARS database. There 
was no language restriction. Japanese medical literature was assessed with the help of the 
Bodleian Library, University of Oxford. Papers in Turkish were assessed with the help of a 
native speaker. All retrieved trials were assessed for possible inclusion by RFB and two co-
reviewers. All trials to be considered for inclusion were assessed for quality using the 
Oxford quality scale103 and for validity using the Oxford Pain Validity Scale (OPVS)104 by 
RFB and  EK, and in the majority of cases together with a third co-reviewer, until consensus 
was reached. Data was extracted according to pre-hoc decision. Authors were contacted in 
order to acquire missing data. Meta-analysis was performed where appropriate (Paper II). 
For dichotomous outcomes, relative risks, and for continuous outcomes, weighted mean 
differences (WMD), were calculated using RevMan 4.2 software127 
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4. Results and discussion of papers   
4.1 Paper I  
Bell RF, Sivertsen Å, Mowinckel P, Vindenes H. A bilateral clinical model for the study of 
acute and chronic pain after breast-reduction surgery. Acta Anaesthesiol Scand 2001; 45 
(5):576-582 
 
Results 
 
VAS pain intensity scores: the model demonstrated a clear difference between lidocaine and 
placebo-treated breasts. The sum of VAS scores for pain intensity was significantly lower in 
the lidocaine group than in the placebo group for the entire registration period of 10 hrs after 
surgery. Regarding chronic postoperative pain there was no pain on testing at 6 months, 
however 3 patients reported ongoing periodic pain. There was no difference between 
lidocaine and placebo-treated breasts at 6 months.  
 
Quantitative sensory testing: Five patients exhibited large changes in temperature thresholds 
(±5°C) 11 days after surgery, with no difference between lidocaine and saline-treated 
breasts. Three of these patients reported ongoing periodic pain at six months, and exhibited 
significant thermal threshold changes, with no difference between lidocaine and placebo-
treated breasts. 
 
 57 
Discussion 
Chronic pain after surgery is common120. Postoperative pain intensity has been shown to be 
a predictive of chronic postoperative pain128 129 130, and it has been suggested that 
preemptive analgesia may reduce the risk of chronic postoperative pain.This has been been 
demonstrated in several clinical trials 131 38. The hypothesis of preemptive analgesia was 
initially received with great enthusiasm, however no major clinical benefits have as yet been 
documented 132. Most studies in postoperative pain have focused on pain relief in the early 
postoperative period, and not on the development of chronic postoperative pain.  
 
The advantageous aspects of the model we describe are that:  
1. It is bilateral, with the patient serving as her own control.  
2. The patients undergo sensory assessment with QST, using a thermotester which delivers 
specific stimuli, testing temperature perception thresholds. QST is thought to be 
especially valuable in detecting impaired small fibre function which may be a factor in 
the chronification of acute pain. Quantitative sensory testing systems have been 
specifically developed to assess and quantify sensory function in patients with 
neurological symptoms. Perioperative testing with long term follow-up may conceivably 
contribute to a better understanding of the mechanisms involved in persistent 
postoperative pain. A report by the Therapeutics and Technology Assessment 
Subcommittee of the American Academy of Neurology in 2003 concluded that QST is a 
potentially useful tool for measuring sensory impairment for clinical and research 
studies133. In our study it was interesting to note that the three patients who reported 
ongoing pain at 6 months also exhibited marked thermal threshold changes.  
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3. It involves a long-term follow-up regarding pain and sensory changes. This is in 
accordance with recommendations for clinical trials in postoperative pain114 123.  
 
The limitation of the model is that it is restricted to breast interventions and to the use of a 
local agent, such as a local anaesthetic.  
 
Dahl and Moiniche123 have extensively discussed the concept of preemptive analgesia and 
suggest that the major problem is not nociception, but the prevention of central sensitisation. 
As suggested in the paper, investigation of longer-lasting local anaesthetic or continuous 
application would be of interest. Prevention of central sensitisation in the clinical situation 
may be difficult, and Dahl et al122 123 recommend that future trials should investigate 
combinations of different classes of drug, such as ketamine, dextromethorphan or 
gabapentin, all  of which have demonstrated anti-hyperalgesic potential in clinical trials of 
postoperative pain. It would be interesting to test the effect of ketamine in this model since it 
is thought to have a local effect via peripheral NMDA receptors, and the expression of 
peripheral NMDA receptors has been shown to increase under conditions of inflammation17 
18
. An animal study has demonstrated that topical ketamine blocks topical morphine 
tolerance in mice134. An experimental study in healthy volunteers showed that local 
treatment with ketamine inhibits the development of secondary hyperalgesia in a burn 
model135. A randomised, controlled clinical study in postoperative pain also reported 
peripheral effects of ketamine136, however the group size in this trial was very small, less 
than 10 patients per group. A randomised placebo-controlled trial in patients with 
neuropathic pain syndromes (diabetic neuropathy, postherpetic neuralgia, and postsurgical/ 
posttraumatic pain) found no difference between 1% topical ketamine and placebo137.  
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Since the publication of this paper new drugs, such as peripheral opioids, have been 
developed. The existence of an endogenous peripheral analgesic system is well-
documented22 138. Using an in-vitro nerve-skin preparation from rats, peripherally delivered 
opioid (morphine) has recently been shown to directly inhibit the activity of cutaneous 
nociceptors under conditions of inflammation139. A peripheral opioid such as the -agonist 
frakefamide140 could therefore also be an interesting drug to investigate in this model.  
 
Improving the model 
The model could be applied to patients undergoing bilateral breast augmentation which is 
generally considered to be a more painful procedure than breast reduction and which has 
been shown be associated with chronic postsurgical pain130. This may further improve the 
sensitivity of the model. As suggested in the paper, time-consuming sensory testing with von 
Frey filaments, and VAS measurements on coughing could be eliminated, since these 
provided no additional useful information. Assessment of pain relief in addition to pain 
intensity, and reporting of patient treatment preference would also improve the model. 
 
 Improving the paper- retrospective critical comments 
 
The process of randomisation and allocation concealment should have been described. The 
number of patients should have been at least 10 (giving a minimum of 10 breasts in each 
group)88. No adverse effects were registered and this should have been stated, together with 
the method of assessment of adverse effects. The clinical significance of the demonstrated 
difference in pain scores versus the statistical significance, should also have been discussed.  
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4.2 Paper II   
Bell RF, Dahl JB, Moore RA, Kalso E. Perioperative ketamine for acute postoperative pain. 
The Cochrane Database of Systematic Reviews 2006, Issue 1. Art.No.:CD004603. DOI: 
10.1002/14651858.CD004603.pub2. 
Bell RF, Dahl JB, Moore RA, Kalso E. Peri-operative ketamine for acute post-operative 
pain. A quantitative and qualitative systematic review (Cochrane review) Acta Anaesthesiol 
Scand 2005;49(10):1405-1428  
 
Results 
Thirty-seven randomised, controlled trials with a total of 2137 patients, of which 1210 
received ketamine, and 53 treatment arms were included. Thirty-two trials used racemic 
ketamine, four used S(+) ketamine and one used the  R(-) isomer. The trials were 
heterogenous and varied in regard to timing and route of administration and dose of 
ketamine. Data from 10 trials reporting the same outcome (24hr patient controlled analgesia 
(PCA) morphine consumption) was combined. The meta-analysis found that ketamine 
reduced 24hr postoperative PCA morphine consumption. In addition, 26 trials reported 
nausea and/or vomiting as dichotomous data. Quantitative analysis of this data found that 
ketamine reduced postoperative nausea and/ or vomiting. 
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Discussion 
Paper II is a quantitative and qualitative systematic review. The objective of the review was 
to establish the evidence base for the efficacy and tolerability of perioperative ketamine in 
the treatment of acute postoperative pain. At the commencement of this paper, no systematic 
review on the topic had been published, however two quantitative and qualitative systematic 
reviews on perioperative ketamine141 142 were published during the preparation of the paper. 
These reviews are briefly mentioned in paper II and will be further discussed below. 
 
That ketamine is a “hot topic” in pain treatment is evidenced by the abundance of reports 
and trials. A search of PubMed in May 2006 revealed 13 narrative reviews, a literature 
review based on an electronic search of the MEDLINE database from 1966-1998 143 and five 
systematic reviews on ketamine for pain treatment, including papers II and III. In addition, 
there were six narrative reviews on NMDA receptor antagonists for pain treatment and one 
qualitative systematic review on NMDA receptor antagonists in “preventive analgesia”.  
 
In the qualitative systematic review144 on NMDA receptor antagonists for ‘preventive 
analgesia’, the authors searched MEDLINE and EMBASE for randomised, double-blinded 
trials of NMDA receptor antagonists given during the perioperative period. The trials were 
assessed for quality using the Oxford Quality scale103. The primary outcome to be 
considered was ‘preventive analgesia’, defined as analgesia beyond five half lives of the 
drug under examination. The conclusions of the review were that ‘both ketamine and 
dextromethorphan produced a significant preventive analgesic benefit in 58% and 67% of 
studies, respectively’. 
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Schmid et al143 investigated low-dose ketamine for postoperative pain. This review was 
based on a search of MEDLINE with search strategy not described. Twenty-eight 
randomised, prospective, controlled double-blind trials reporting pain scores were included, 
but were not subjected to quality and/ or validity assessment. A number of these trials were 
excluded by our own review due to methodological problems. The conclusions of this 
review were that ‘ketamine may provide clinicians with a tool to improve postoperative pain 
management and to reduce opioid related adverse effects’. 
 
Comments on the meta-analysis 
Efficacy data 
The finding of the quantitative analysis, that perioperative ketamine reduces 24hr PCA 
morphine consumption needs to be interpreted in the light of several factors. The ketamine 
regimes being compared in these trials differed (table 5).  
 
Table 5. Trials included in the meta-analysis for efficacy 
                        Trial             Surgical procedure/ ketamine 
Roytblatt 1993 Elective open cholecystectomy /Preincisional 
bolus of ketamine 0.15 mg/kg IV 
Javery 1996 Lumbar microdiscectomy / Postoperative IV 
PCA ketamine 1 mg/bolus 
Stubhaug 1997 Nephrectomy (live kidney donors) /Ketamine 
bolus 0.5 mg/kg IV + infusion 2 mcg/kg/min 
IV for 24 hrs from start of study 
Ilkjær 1998 Elective nephrectomy or operation on pelvic 
structures / Ketamine bolus 10 mg IV before 
surgical incision/10 mg/h IV postoperative 
infusion 
Adriaenssens 1999 Laparotomy / Ketamine IV infusion, initially 
10 mcg/kg/min for 48 hours after surgery 
Menigaux 2000 (2 
ketamine treatment 
arms) 
Knee surgery: elective arthroscopic /  
1. Preincisional ketamine bolus 0.15 mg/kg 
IV  
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2. At wound closure: ketamine bolus 0.15 
mg/kg  IV 
Guignard 2002 Abdominal surgery / Ketamine bolus 0.15 
mg/kg IV + infusion 2 mcg/kg/min IV from 
prior to incision until skin closure 
Jaksch 2002 Elective arthroscopic anterior cruciate 
ligament repair / S(+) ketamine bolus 0.5 
mg/kg IV + infusion 2mcg/kg/hr IV until 2 
hours after emergence from anaesthesia 
Guillou 2003 Major abdominal / After surgery: initial 
ketamine bolus 0.5 mg/kg IV + infusion 
2mg/kg /min IV for 24 hr and 1mg/kg/min IV 
from 24-48 h 
Snijdelaar 2004 Radical retropubic prostatectomy / 
Intraoperative S (+) ketamine bolus 0.1 mg/kg 
IV, followed by continuous infusion of 0.002 
mg/kg/min IV until skin closure+ post-
operative IV PCA S (+) ketamine 0.5 mg 
bolus 
 
The advisability of combining data from trials which use different timing, duration and route 
of administration of ketamine may be questioned. Eight of the included trials used racemic 
ketamine, and two used S(+) ketamine. In the absence of more homogenous trials, a common 
denominator was found in that all ten trials report the same outcome. The conclusions are 
therefore limited, and issues relating to dose, timing and route of administration unresolved.  
 
Two quantitative reviews on ketamine for postoperative pain were published during the 
preparation of our review on the same topic. Elia et al142 chose to restrict quantitative 
analysis to a  “clinically homogenous” subgroup of 16 trials examining intravenous bolus 
and/ or infusions of ketamine in patients undergoing general anaesthesia. Cumulative 
morphine consumption at 24 hours based on data from four trials gave similar results to our 
own analysis of 24hour PCA morphine consumption in 10 trials. Subramaniam et al141 
performed quantitative analysis of VAS data from four subgroups stratified according to 
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route of administration, but did not perform quantitative analysis of data concerning 
morphine consumption.  
 
An interesting observation in our data was the fact that increasing the dose of ketamine 
above an estimated dose of 30 mg/ 24 hours did not appear to increase the morphine-sparing 
effect. Since the adverse effects of ketamine are dose-dependent, it could be speculated that 
the true clinical potential of ketamine in pain treatment lies in the use of low doses, adjuvant 
to opioid, since concurrent administration with opioid has been shown to increase the 
distribution of ketamine into the brain66.  
 
Tolerability data 
    Two trials did not report on adverse effects. Twelve trials did not report dropouts/      
withdrawals. The quantitative analysis of the combined nausea and/or vomiting data from 26 
trials indicated that ketamine reduces PONV. The data was again heterogenous, with the 
methods of assessment of adverse effects differing between trials (table 6). Different 
methods of collecting adverse events can produce different results117. The results of the 
meta-analysis should therefore be interpreted with this in mind and may be compared with 
the findings from the other two systematic reviews on perioperative ketamine. Elia et al142 
performed quantitative analysis on dichotomous data from five trials reporting nausea, four 
trials reporting vomiting and three trials reporting nausea or vomiting, and found no 
significant difference from control. Subramaniam et al141 performed quantitative analysis 
regarding the incidence of nausea and vomiting on data from 16 trials and found “ a trend 
towards less PONV in ketamine-treated patients compared with patients who received 
opioids alone”. 
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Table 6. Post-operative nausea and/ or vomiting (PONV): method of assessment in trials 
included in meta-analysis 
 
                          Trial PONV:method of assessment 
Roytblatt 1993 ”Reported if present” 
Lauretti 1996  Direct questioning (VAS 0-10) 
Stubhaug 1997 Direct questioning  (VRS 0-3) 
Abdel-Ghaffar 1998 Not stated 
Chia 1998 Not stated 
Adriaenssens 1999 Direct questioning  
Hercock 1999 Direct questioning (NRS) 
Suzuki 1999 Direct questioning (VAS) 
Tan 1999  Regularly ”assessed” 
Kirdemir 2000 Not stated 
Menigaux 2000 ”If present….noted” 
Himmelseher 2001 ”noted” 
Menigaux 2001 Regularly ”recorded” 
Papaziogas 2001 Direct questioning 
Subramaniam (a) 2001 Direct questioning 
Subramaniam (b) 2001 Direct questioning 
Guignard 2002 ”Recorded” 
Jaksch 2002 ”Recorded” 
Santawat 2002 Direct questioning (VRS 0-3) 
Guillou 2003 Not stated 
Kararmaz 2003 Direct questioning (VRS 0-3) 
Xie 2003 ”Observed” 
Unlugenc 2003 ”Recorded” 
Argiriadou 2004 ”Noted” 
Kakinohana 2004 ”Recorded” 
Snijdelaar 2004 Direct questioning (nausea: VAS 
0-10; vomiting: present or 
absent) 
VAS: visual analogue scale 
NRS: Numerical rating scale 
VRS: verbal rating scale 
 
 
Methodological issues 
In general, the quality and validity scores in these trials were high. The included trials used 
either a placebo control, or a ”placebo-like” control- (morphine versus (morphine + 
ketamine)). Polypharmacy is common in the perioperative period, and it was attempted to 
standardise anaesthetic regimes and postoperative pain treatments as far as possible. The 
standard of reporting was generally good, except with regard to adverse effects as mentioned 
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above. Group sizes were generally small and there was considerable heterogeneity of 
ketamine treatment regimens. The largest group of studies investigated a preincisional bolus, 
and/ or a perioperative IV infusion of ketamine, and it is suggested that future trials could 
focus on this route and duration of administration.  Finally, the question of chronic 
postoperative pain is yet to be addressed. Only one included trial had a long term (up to 12 
months) follow-up145. 
 
Several randomised, controlled trials on perioperative ketamine for acute post-operative 
pain146 147 148 149 have been published since this Cochrane review and it will be interesting to 
see what information the accumulating data provides.  
 
 
 
4.3 Paper III  
Bell R, Eccleston C, Kalso E. Ketamine as adjuvant to opioids for cancer pain. The 
Cochrane Database of systematic reviews 2003, Issue 1. Art No.:CD003351. 
DOI:10.1002/14651858. CD003351 
Bell RF, Eccleston C, Kalso E. Ketamine as an adjuvant to opioids for cancer pain. A 
qualitative systematic review. J Pain Symptom Manage 2003;26;3:867-875 
 
Results 
Four randomised, controlled trials met the inclusion criteria. Two were excluded due to 
methodological flaws. Both trials concluded that ketamine improves the effectiveness of 
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morphine in the treatment of cancer pain. Pooling of data was not appropriate due to the 
small number of patients and and the presence of clinical heterogeneity. Some patients 
experienced hallucinations on both ketamine plus morphine, and morphine alone. No other 
serious adverse effects were reported.  
 
Discussion 
 
Ketamine is widely used as an adjuvant to opioids for the treatment of refractory cancer pain 
and the treatment is described in leading textbooks on pain treatment and palliative care150 
151
. This is a qualitative systematic review with the objective of establishing the evidence-
base for this practice. No other systematic review on this topic has been published.  
 
Efficacy and tolerability data 
 
Only four RCTs were identified and the data was heterogenous. Of the two included trials, 
one lasted only hours and investigated the effect of intravenous ketamine, while the other 
lasted weeks (exact duration not given) and studied the effect of intrathecal ketamine.  
 
In addition to the four RCT’s, a number of open-label studies and case reports were 
retrieved. While case reports cannot provide efficacy data, they can be a source of useful 
information on adverse effects. In general adverse effects were not reported as severe. 
Hallucination and sedation were the most commonly reported and were related to higher 
doses of ketamine. Two case reports described toxic effects of continuous spinal 
administration of ketamine over 7-21 days72 73. An additional case report was recently 
published describing good pain relief but severe histological abnormalities of spinal cord 
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and nerve roots after continuous intrathecal administration of S(+) ketamine in a patient with 
intractable cancer pain74. One case report also described acute generalised hyperalgesia in a 
patient following abrupt cessation of a several week long subcutaneous infusion of ketamine 
120-200 mg/ 24 hours152. Inflammation of the needle site during subcutaneous infusion has 
also been reported as a common problem152 153 154. 
 
Since the preparation of this review further case reports155 156 157 and a retrospective audit158 
have been published, representing different countries including Turkey, the Netherlands, 
Canada and Italy. From the literature it is evident that ketamine is used primarily for the 
treatment of refractory pain and that clinicians consider it to be a useful drug in this setting. 
Indeed, paper III provoked a disappointed reaction from a group of experienced clinicians107 
159
.  
 
Methodological issues  
 
Both included trials had very small numbers of patients, 10 in one trial and 20 in the other, 
and both employed a crossover design. One trial used a placebo control, while the other used 
a “placebo-like” control (morphine versus morphine plus ketamine). The two excluded trials 
were from the same research group and were considered to have flawed methodology, 
employing a fixed maximum dose of rescue morphine, and morphine consumption as 
outcome.  
 
Given the widespread use of ketamine in the palliative care setting, this qualitative 
systematic review indicates a need for well-designed, randomised, placebo-controlled trials. 
Future RCT’s on ketamine as an adjuvant to opioids for cancer pain should be looking at 
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efficacy, adverse effects and optimal dose and route of administration. Since sedation is a 
commonly reported adverse effect in case reports of ketamine as adjuvant to opioid, the 
question of effective trial blinding is relevant. This could be achieved by using an active 
comparator (for example a low dose of midazolam), in addition to a placebo control. 
Alternatively, direct questions could be made to investigator and patient in order to check for 
blinding. Patient treatment preference would also provide important information.  
 
The literature demonstrates widely differing clinical practice concerning ketamine dose and 
route of administration. From the case reports it appears that the use of ketamine as a 
subcutaneous infusion is common practice. However, providing the cancer patient is able to 
take oral medication, this route of administration is generally preferred45. The use of oral 
ketamine  as an adjuvant is poorly documented. Several case reports and an open label 
study160 report that it is effective in neuropathic pain states, but that adverse effects such as 
drowsiness and nausea are common. N of 1 randomised, controlled trials of oral ketamine in 
patients with chronic pain found that oral ketamine gave increased analgesia in only three of 
21 patients and that adverse effects limited use in approximately 50%161.  In an experimental 
study in healthy volunteers, using an acute burn model, oral ketamine had no effect on 
secondary hyperalgesia or thermal and mechanical pain thresholds162. Racemic ketamine has 
an oral bioavailability of only 17 %64 due to high first passage metabolism. Other possible 
routes of administration are intranasal65 and sublingual. A case series reporting the use of 
sublingual ketamine for breakthrough cancer pain has recently been reported157. 
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4.4 Paper IV  
Bell RF, Wisløff T, Eccleston C, Kalso E. Controlled clinical trials in cancer pain. How 
controlled should they be? A qualitative systematic review. Br J Cancer 2006;94:1559-1567 
 
Results 
Thirty-four randomised, double-blinded, controlled trials on specific oral opioids (morphine, 
hydromorphone, oxycodone) for cancer pain were included. The total number of patients 
enrolled was 1864. Only one study had a placebo control ( nine patients, duration 12 hours) 
and one study had a placebo arm in the first phase (four patients, duration 7±1 days). Thirty-
three of the thirty-four trials were equivalence trials. Only nine trials were scored as 
sensitive. More than 50% of the trials did not report performing power calculations. Only 11 
trials included a description of the pain. The criteria for adequate/ inadequate pain relief was 
clearly defined in only eight trials and no two studies used the same criteria. Only three trials 
assessed and reported psychological variables. 
 
Discussion 
Several systematic reviews163-165 and two comprehensive evidence report/ technology 
assessments166 167 have remarked on the methodological shortcomings of opioid trials in 
cancer pain. In addition, Caraceni et al168 have reviewed cancer pain assessment in clinical 
trials in oncology published between 1999 and 2002. A search of PubMed performed in May 
2006 using the terms: trial methodology AND opioid AND cancer and limited to “Reviews” 
found 14 hits, none of which primarily concerned trial methodology. This paper has 
identified a number of methodological problems and possible areas for improvement in the 
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cancer pain analgesic trial literature.  The general lack of a placebo control in these trials 
raises an interesting question. 
Opioids for cancer pain- what is the evidence?  
Oral morphine is the ”gold standard” opioid for the treatment of cancer pain. In this review 
of trials investigating oral opioids for cancer pain, only one trial had a placebo control, while 
another trial had a placebo control in the pilot phase of the study. In the first of these trials 
which investigated the effect of a loading dose of morphine elixir added to the first dose of 
slow-release morphine tablets, a total of nine patients were treated with a single dose of 
placebo, the study duration being 12 hours169. In the pilot phase of the second trial, where 
three different formulations of slow-release morphine were compared to placebo for 7±1 
days, a total of four patients received placebo treatment170. The assumption for using 
morphine as an active comparatoror in the remaining trials is that it has previously been 
found effective in cancer pain compared to placebo.  But is this the case? 
 
A Cochrane review concluded that oral morphine is effective for cancer pain164. This review 
attempted to bring all of the literature together and included data from randomised trials, 
including open label trials. The authors remarked that the majority of trials are equivalency 
studies designed to show that different formulations of morphine have the same effect, and 
that this makes it difficult to extract information on the effectiveness of morphine per se.  
Furthermore, they underlined that it is unclear whether the trials are sufficiently powered to 
detect a clinically meaningful difference between treatments. Although the Oxford Quality 
Scale scores were generally high, with a median of 4, it was noted that the quality of 
reporting was disappointing, especially in regard to assessment of pain and pain relief. The 
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trials in this review were not scored for validity, and the relevance of a placebo control for 
the demonstration of efficacy is not specifically addressed. 
.  
In a second Cochrane review163, 11 trials investigating hydromorphone in cancer pain were 
included, all of which used  an active comparator. A recent quantitative systematic review on 
oxycodone for cancer pain165 found no placebo controlled trials. An Agency for Healthcare 
Research and Quality (AHRQ) Evidence Report166 looking at the relative efficacy of 
analgesics in cancer pain described the need for placebo controls in order to avoid 
overestimation of treatment effects, at the same time noting  that placebo controls in cancer 
pain trials are ”rare”. More recently, a report by the Norwegian Knowledge Centre for the 
Health Services167 concluded that opioid analgesics ”have good effect on moderate to strong 
cancer pain”. According to this report, ”the general impression from all the studies is that 
opioids are extremely effective in relieving pain in cancer patients” this being ”documented 
in old placebo-controlled studies.” No references were provided in support of this statement. 
In order to obtain the specific references, the authors of the report were contacted, and 
subsequently clarified that the statement pertains to references in the AHRQ report 166. A 
closer examination of the AHRQ references did not provide any supplementary placebo-
controlled trials investigating oral morphine for cancer pain. Table 7 is a summary of 
placebo-controlled trials investigating stronger opioids for cancer pain. 
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Table 7: Randomised, double-blind trials in cancer pain patients comparing stronger opioid 
with placebo 
 
Study N= Drug Route Duration Comments 
Houde et al. 
1960 171 
67  Morphine IM 6 hours Double-blind 
Crossover 
Single dose 
Stambaugh et 
al.  1982 172 
29 (20 
evaluable) 
Butorphanol 
Acetaminophen 
B+A 
PO Up to 6 hours Double-blind 
Crossover 
Single dose 
Stambaugh et 
al 1983 173 
30 Meperidine 
Hydroxyzine 
M+H 
IM 4 days, 1 
treatment per 
day 
Double-blind 
Crossover 
Single dose 
Stambaugh et 
al 1987a 174 
60 (3 
groups) 
Dezocine 
Butorphanol 
IM 7 days Double-blind 
Parallel group 
Single and 
multiple dose  
Stambaugh et 
al. 1987b 175 
43 (40 
evaluable) 
Ciramadol 
Codeine 
PO 6 hours Double-blind 
Crossover 
Single dose 
Hoskin et al. 
1989 169 
20 ( 19 
evaluable) 9 
treated with 
placebo 
Morphine PO 12 hours Double-blind 
Single dose 
Parallel group 
Broomhead et 
al  1997 170 
172 (152 
final day 
efficacy 
data) 
4 treated 
with   
placebo 
Morphine PO 7±1 days   Double-blind 
Parallel group 
Placebo 
control only 
in first phase 
of study 
Farrar et al. 
1998 176 
92 (89 
assessable, 
treated with 
at least one 
unit of 
OTFC and 
one unit of 
placebo) 
fentanyl citrate 
(OTFC) 
OTM Titration 
period + 10 
randomly 
ordered 
treatment 
units (Pain 
evaluated for 
60 minute 
period) 
Double-blind  
Crossover 
Multiple dose 
Breakthrough 
pain 
IM: intramuscular; PO: oral; OTM:oral transmucosal 
Sources: AHRQ nr. 35166, Wiffen et al164 Quigley163, Kongsgaard et al167, Reid et al165 and 
Bell et al (paper IV). In addition, searches were performed on PubMed with limits 
”randomised controlled trial” and search terms : ”fentanyl AND placebo and cancer” / 
”methadone AND placebo AND cancer”. 
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Unless there is a body of data we have been unable to access, these findings raise interesting 
questions regarding the current efficacy data for oral opioids in cancer pain. Even though 
opioids appear clinically effective for cancer pain, the question of how effective is not 
resolved by the literature. Morphine is accepted as the gold standard for cancer pain 
treatment, however placebo-controlled efficacy data in cancer pain is lacking.  
 
In addition to the issue of placebo control, this paper identifies a number of areas where 
methodology in cancer pain drug trials could be significantly improved. In the included trials 
the pain being treated was rarely described, and only a minority of trials defined the criteria 
for treatment effect. Emotional functioning, including assessment of depression and anxiety, 
is a recommended core outcome domain and measure for chronic pain trials 111 112.  
However, in the cancer pain trials, psychological factors were generally not addressed. The 
majority of trials were equivalence studies. The limitations of this type of trial have recently 
been addressed in the revised CONSORT statement125.  Finally, the importance of 
investigating clinically useful outcomes should be emphasised. We need to know which 
patients respond to opioids and which patients do not respond, rather than whether two 
formulations of the same opioid are equally effective.  
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5. Conclusions   
Aim 1: To develop and test a clinical model for use in the study of acute and chronic 
postoperative pain: A bilateral clinical model which is sensitive, and suitable for 
investigating specific local interventions for acute and chronic postoperative pain was tested 
and reported in paper I. 
 
Aim 2: To investigate the current evidence-base for perioperative ketamine in acute 
postoperative pain by preparing a systematic review, and by doing so, to assess the trial 
methodology. Paper II is a quantitative and qualitative systematic review. The results of the 
meta-analysis provides level 1 evidence that ketamine reduces morphine requirements in the 
first 24 hours after surgery, and reduces postoperative nausea and vomiting. Adverse effects 
were mild or absent. The data is heterogenous and cannot be translated into a specific 
treatment regime. The quality and validity scores of the individual trials were generally high, 
however there was considerable clinical heterogeneity. Issues of optimal dose, timing and 
route of administration of ketamine are not resolved by the current literature. 
 
Aim 3: To investigate the current evidence-base for ketamine as an adjuvant to opioid for 
cancer pain, and in doing so, to assess the trial methodology: The current evidence is 
insufficient to make conclusions regarding the benefits and harms of ketamine as adjuvant to 
opioid for cancer pain. Conclusions regarding trial methodology were not possible due to the 
limited number of trials. A large number of clinical case reports demonstrate widely varying 
practice with regard to dose and route of administration. 
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Aim 4: To perform a systematic review of the methodology used in analgesic trials in cancer 
pain, with focus on oral opioids.  Paper IV is a qualitative systematic review. In this paper,  
significant limitations in the methodology used in trials of oral opioids for cancer pain are 
identified. There is a need for standardised trial design and specific validity criteria for 
cancer pain. Concrete methodological recommendations for future trials are made.   
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6. Implications for clinical practice and future 
research   
6.1 Trial methodology  
Pain is difficult to study in the context of a randomised, controlled trial. This doctoral work 
pinpoints a need for uniform standards of reporting and more rigorous trial design, especially 
in analgesic studies in cancer pain. The poor quality of reporting and the methodological 
limitations of the research on opioids for cancer pain has been mentioned in previous 
reports166 164, but does not seem to have  resulted in any significant discussion or change in 
strategy. Considering the difficulties of research in this patient population, efforts to 
standardise trial design and reporting are needed. Whilst one trial design for all opioid trials 
in cancer pain is not feasible, a set of trial designs could be useful. Such a document is 
beyond the scope of this thesis, but could conceivably result from a consensus meeting 
between palliative care clinicians, pain researchers and statisticians having an interest in 
evidence-based pain relief. Such a consensus meeting which could be be comparable with 
the initiatives of the IMMPACT recommendations for chronic pain trials111 112 is proposed in  
Paper IV. 
 
6.2 Perioperative ketamine for acute postoperative pain   
Clinical practice 
Acute pain usually responds well to drug treatment (opioids), but opioid-related adverse 
effects are well documented and may contribute to increased in-hospital morbidity and costs. 
The rational for using perioperative ketamine should primarily be to reduce the total 
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perioperative opioid dose in patients undergoing specific surgical procedures where large 
doses of opioids are traditionally required. It may also be useful in opioid-tolerant surgical 
patient groups, such as drug abusers and cancer pain patients. Although there is no data to 
support the hypothesis, another rational for using ketamine would be in association with 
especially painful procedures involving nerve damage, with the aim of reducing hyperalgesia 
and possibly inhibiting or reducing the development of chronic postoperative pain. This type 
of treatment should be performed in the context of a clinical audit. 
 
Future research 
Since the spinal administration of ketamine is associated with unclear toxicity issues70, 
future research on perioperative ketamine should focus on the common practice of 
intravenous administration, and on the question of optimal dose, and duration of treatment. 
The interesting question is whether perioperative ketamine hastens recovery, reduces 
morbidity and reduces the development of chronic postoperative pain. Whether there is a 
clinical benefit of the demonstrated opioid-sparing effect of perioperative ketamine needs to 
be investigated. Clinically meaningful trial outcomes include measures of postoperative 
recovery. Opioid-related adverse effects should be carefully assessed and reported. Adverse 
effects should be reported as dichotomous data, and include a description of the method of 
assessment. 
Studies in surgical patient groups where opioid-sparing is of particular importance, for 
example, cancer patients on high opioid doses, would be of interest. Studies with long-term 
follow-up in patients undergoing procedures known to be associated with persistent 
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postoperative pain, such as thoracotomy, are also indicated. Whether the isomers have 
advantages over the racemate is another relevant area for investigation. 
6.3 Ketamine as an adjuvant to opioid for cancer pain   
Clinical practice 
Although the evidence is limited and does not permit recommendations for practice, this  
does not mean that the treatment does not work, or that clinicians should cease to treat 
refractory neuropathic cancer pain with low-dose ketamine. It simply means we currently 
lack reliable data.  Findings from both Cochrane reviews support clinical observations that 
the morphine-sparing effect and the adverse effects of ketamine are dose-dependent, with 
low doses giving morphine-sparing and high doses producing adverse effects. The true 
clinical potential of ketamine for pain treatment in the palliative care patient population may 
lie in the use of low doses (for example 1 mg/kg/day as a subcutaneous infusion), adjuvant 
to opioid.  
 
Future research 
From the literature it is obvious that clinicians consider ketamine to be a useful drug in the 
treatment for refractory cancer pain. It is therefore important to document this treatment, and 
to learn more about the mechanisms of action, in order to optimalise the use of this drug.  
Randomised, controlled trials investigating the common practice of subcutaneous ketamine 
as adjuvant to opioid are needed. The use of oral ketamine should be documented initially in 
clinical audits, and if the treatment proves promising, be investigated in randomised, 
controlled trials. The peripheral effects of topical ketamine e.g. in the treatment of painful 
mucositis or pressure sores, is another area for investigation. Breakthrough or incident pain 
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is a common clinical problem and difficult to treat with analgesics. Ketamine in a rapid-
acting formulation may prove useful in this context. The single published RCT on intranasal 
ketamine for breakthrough pain was performed on a mixed patient group, predominantly 
patients with chronic, non-cancer pain. Trials of longer duration in cancer pain patients are 
needed.  
 
The Cochrane review on ketamine as an adjuvant to opioid for cancer pain (paper III) will be 
updated in the course of 2006. A preliminary search of PubMed in March 2006 indicated 
that RCT’s are still lacking. As a direct result of this doctoral thesis, two trials have been 
designed. A randomised, double-blind placebo-controlled crossover study will investigate 
subcutaneous ketamine as adjuvant to morphine for refractory cancer pain. The second trial 
will investigate the peripheral effect of ketamine for painful mucositis in cancer patients. 
This is a randomised placebo-controlled crossover study comparing ketamine and morphine 
mouthwashes, and placebo.  
 
Considering the postulated role of the NMDA receptor in opioid tolerance, together with the 
pre-clinical data reporting that low plasma concentrations of alfentanil increase the 
distribution of ketamine into the brain66,  further studies investigating the opioid/ ketamine 
relationship are warranted. The pharmacokinetics of ketamine as adjuvant to morphine are of 
primary interest since combining these drugs is common clinical practice. 
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